Drug
Gemcitabine clinical trials
Also written Gemzar, LY188011 and FF 10832.
- studies test it
- 1,575
- open now
- 193
- in phase 3
- 174
- first study started
- 1995
Keep track of what changes. Save the Gemcitabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
- Gemzar
- 27
Studies by the year they started
1,558 studies that test it; most in 2006 (84); 2 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1996 | 1 |
| 1997 | 14 |
| 1998 | 27 |
| 1999 | 38 |
| 2000 | 35 |
| 2001 | 52 |
| 2002 | 50 |
| 2003 | 75 |
| 2004 | 75 |
| 2005 | 83 |
| 2006 | 84 |
| 2007 | 72 |
| 2008 | 64 |
| 2009 | 58 |
| 2010 | 45 |
| 2011 | 58 |
| 2012 | 56 |
| 2013 | 65 |
| 2014 | 52 |
| 2015 | 60 |
| 2016 | 56 |
| 2017 | 40 |
| 2018 | 57 |
| 2019 | 45 |
| 2020 | 38 |
| 2021 | 35 |
| 2022 | 33 |
| 2023 | 46 |
| 2024 | 56 |
| 2025 | 39 |
| 2026 | 47 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 11
- Phase 1
- 477
- Phase 2
- 1,054
- Phase 3
- 174
- Phase 4
- 13
- No phase
- 33
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 30
Who runs them
Industry 307 · Other 1,268
National Cancer Institute (NCI) (71) · Eli Lilly and Company (70) · M.D. Anderson Cancer Center (47) · Memorial Sloan Kettering Cancer Center (38) · Alliance for Clinical Trials in Oncology (29) · Fudan University (20) · Sun Yat-sen University (20) · Hoffmann-La Roche (19)
Often tested with
Tested in the same studies.
Cisplatin (368) · Paclitaxel (292) · Albumin-Bound Paclitaxel (197) · Carboplatin (137) · Docetaxel (131) · Oxaliplatin (127) · Capecitabine (82) · Bevacizumab (72)
Studies
Open first, then newest update. How each study uses Gemcitabine is read from its arms, and is right about nine times in ten.
Testing it · 1,575
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as Gemcitabine & oxaliplatin
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07888621Written as Gemcitabine
- A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerRecruitingPhase 1/2Theriva Biologics SLNCT07701486Written as Nab-paclitaxel + Gemcitabine
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT05139017Written as Gemcitabine
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as Gemcitabine
- Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic CancerRecruitingPhase 1City of Hope Medical CenterNCT06454383Written as Gemcitabine
- Histotripsy in Biliary Tract CancerRecruitingNot applicableNYU Langone HealthNCT07853690Written as Gemcitabine
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Gemcitabine & oxaliplatin
- Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaRecruitingPhase 1Emory UniversityNCT07144254Written as Gemcitabine
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as gemcitabine
- A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingPhase 4AstraZenecaNCT07876817Written as Gemcitabine
- Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaRecruitingPhase 2Jinbo YueNCT07030140Written as Gemcitabine
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingPhase 2National Cancer Institute (NCI)NCT06064097Written as Gemcitabine
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingPhase 2Hoffmann-La RocheNCT06806033Written as Gemcitabine
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingPhase 1/2Mayo ClinicNCT06704191Written as Gemcitabine
- A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic CholangiocarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05967182Written as Gemcitabine
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225Written as Gemcitabine
- DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingPhase 1/2Ohio State University Comprehensive Cancer CenterNCT07705919Written as Gemcitabine
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT07226856Written as Gemcitabine
- Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG TherapyRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07000084Written as Gemcitabine
See all 1,575 studies that test Gemcitabine →
Given in every arm · 690 — Gemcitabine is usual care beside what is tested
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Gemcitabine Hydrochloride
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03618550Written as gemcitabine
- Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06440993Written as Gemcitabine
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Gemcitabine + Nab-paclitaxel
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER StudyRecruitingPhase 3NRG OncologyNCT07097142Written as Gemcitabine
- Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04891289Written as Gemcitabine
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Artios Pharma LtdNCT04657068Written as Gemcitabine
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 2Massachusetts General HospitalNCT07711483Written as Gemcitabine & oxaliplatin
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06498648Written as Gemcitabine
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Gemcitabine Hydrochloride
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Michael Spinner, MDNCT07021989Written as Gemcitabine
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Gemcitabin
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingPhase 3BioNTech SENCT07173751Written as Gemcitabine
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Gemcitabine
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]RecruitingPhase 2Nanjing Leads Biolabs Co.,LtdNCT07111546Written as Gemcitabine Hydrochloride for Injection
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06623422Written as Gemcitabine
- Repurposing Mefloquine for Pancreatic Cancer TreatmentNot yet recruitingPhase 1University of FloridaNCT07875907Written as gemcitabine and nab paclitaxel
- Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic AdenocarcinomaRecruitingPhase 1Oncomatryx Biopharma S.L.NCT07377045Written as Nab-paclitaxel + Gemcitabine
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT05382559Written as Gemcitabine
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Gemcitabine Hydrochloride
Showing 20 of 690.
As the comparator · 223 — what is tested is compared with Gemcitabine
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Immuneering CorporationNCT07562152Written as GnP
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Gemcitabine
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Gemcitabine
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingPhase 2National Cancer Institute (NCI)NCT06770582Written as Gemcitabine
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156Written as Gemcitabine
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Gemcitabine
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Gemcitabine
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Gemcitabine
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3AstraZenecaNCT06467357Written as Gemcitabine
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Gemcitabine
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingPhase 3SystImmune Inc.NCT07869836Written as Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
- Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBCRecruitingNot applicableTianjin Medical University Second HospitalNCT07749924Written as Adjuvant Intravesical Chemotherapy
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Gemcitabine
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as Gemcitabine
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingPhase 3GenmabNCT07604766Written as Gemcitabine
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Gemcitabine
- A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)RecruitingPhase 3GlaxoSmithKlineNCT07684612Written as Gemcitabine
- A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06919965Written as Gemcitabine
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial CarcinomaRecruitingPhase 3Peking University First HospitalNCT07498907Written as Gemcitabine (1000 mg/m2)
- A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06319820Written as Gemcitabine
Showing 20 of 223.
Codes
What other systems call Gemcitabine · ClinicalTrials.gg INT006865
- MeSH (NLM) D000093542GemcitabineConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) B76N6SBZ8RGEMCITABINEConfirmed FDA, Wikidata
- RxNorm 12574Confirmed FDA, Wikidata
- Wikidata Q414143gemcitabineConfirmed FDA, Wikidata
- NCI Thesaurus C66876GemcitabineOne source FDA
- DrugBank DB00441One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000093542 | Gemcitabine | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | B76N6SBZ8R | GEMCITABINE | Confirmed FDA, Wikidata |
| RxNorm | 12574 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414143 | gemcitabine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C66876 | Gemcitabine | One source FDA |
| DrugBank | DB00441 | — | One source Wikidata |
Also registered as gemcitabine hydrochloride (UNII U347PV74IL · RxNorm 236234).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.